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Abstract
Background:  There is recent evidence suggesting that rosiglitazone increases death from
cardiovascular causes. We investigated the direct effect of this drug on atheroma using 3D carotid
cardiovascular magnetic resonance.
Results: A randomized, placebo-controlled, double-blind study was performed to evaluate the
effect of rosiglitazone treatment on carotid atherosclerosis in subjects with type 2 diabetes and
coexisting vascular disease or hypertension. The primary endpoint of the study was the change
from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured
by carotid cardiovascular magnetic resonance. Rosiglitazone or placebo was allocated to 28 and 29
patients respectively. Patients were managed to have equivalent glycemic control over the study
period, but in fact the rosiglitazone group lowered their HbA1c by 0.88% relative to placebo (P <
0.001). Most patients received a statin or fibrate as lipid control medication (rosiglitazone 78%,
controls 83%). Data are presented as mean ± SD. At baseline, the carotid arterial wall volume in
the placebo group was 1146 ± 550 mm3 and in the rosiglitazone group was 1354 ± 532 mm3. After
52 weeks, the respective volumes were 1134 ± 523 mm3 and 1348 ± 531 mm3. These changes (-
12.1 mm3 and -5.7 mm3 in the placebo and rosiglitazone groups, respectively) were not statistically
significant between groups (P = 0.57).
Conclusion: Treatment with rosiglitazone over 1 year had no effect on progression of carotid
atheroma in patients with type 2 diabetes mellitus compared to placebo.
Background
The prevalence of diabetes is increasing exponentially
worldwide, and type 2 diabetes accounts for 90% of cases
[1]. Insulin resistance is a fundamental feature of type 2
diabetes and is associated with increased cardiovascular
risk, which accounts for up to 80% of deaths in these
patients [2,3]. The United Kingdom Prospective Diabetes
Study (UKPDS) demonstrated that intensive blood glu-
cose control with insulin or sulphonylurea in type 2 dia-
betic patients had only a limited effect on the incidence of
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cardiovascular events, indicating the necessity for new
treatment strategies [4].
The thiazolidinediones are a class of oral hypoglycemic
drugs which have gained rapid and widespread accept-
ance into clinical practice. Their pharmacological action is
through the reduction of insulin resistance by sensitizing
muscle, liver, and adipose tissue to insulin, and treatment
is associated with delayed progression to type 2 diabetes
[5,6]. Their agonist effect is mediated by peroxisome pro-
liferator activated receptor gamma (PPARγ), a nuclear hor-
mone receptor, with effects on carbohydrate and lipid
metabolism, fat cell differentiation, and gene regulation
similar to those seen when insulin combines with its
receptor [7]. Two glitazones are available for clinical use:
pioglitazone and rosiglitazone. Both have been shown to
lower hemoglobin A1c (HbA1c) to a similar extent but they
have distinct lipid modulation properties [8]. Both drugs
raise high-density lipoprotein cholesterol (HDLc), but
pioglitazone reduces triglyceride levels while rosiglita-
zone has shown either no consistent change or an increase
in levels. Additionally, low-density lipoprotein choles-
terol (LDLc) concentration is contentious [8,9], studies
have generally suggested a reduction with pioglitazone,
but an increase with rosiglitazone, although the shift from
small dense LDLc to a large buoyant phenotype may be
less atherogenic [10].
The beneficial effect of rosiglitazone on plaque progres-
sion has been shown in animal and human subjects [11-
13]. In a study of 92 sub-optimally controlled type 2 dia-
betic patients who were randomised to either metformin
or rosiglitazone treatment, Stoker et al demonstrated that
there was a significant reduction in carotid intima-media
thickness (IMT) after 24 weeks in the rosiglitazone group
[14]. Additionally, the effect of rosiglitazone on carotid
intima-media thickness (IMT) over 12 months was stud-
ied in patients with type 2 diabetes and the insulin resist-
ance syndrome and no statistically significant difference
from placebo was shown [15]. However, this study sug-
gested that rosiglitazone may have a beneficial effect in
overt diabetes compared with the pre-diabetic group.
Carotid IMT is an important surrogate marker of cardio-
vascular risk and there is a linear relationship between this
measure and the angiographic presence and severity of
coronary artery disease [16-21]. Therapeutic intervention
with antiplatelet agents, angiotensin-converting enzyme
(ACE) inhibitors, β-blockers, and statins prevent progres-
sion of carotid IMT and have been shown to favorably
impact on cardiovascular morbidity and mortality [22-
25]. Of these, the most potent drugs are the statins
[20,26].
High-resolution carotid cardiovascular magnetic reso-
nance (CMR) is a comparatively new tool for the assess-
ment of carotid atheroma which evaluates arterial wall
remodeling in a 3-dimensional (3D) manner with good
reproducibility in carotid disease of 4.4%, which allows
small sample sizes [27,28]. For example, CMR showed
atheroma regression using simvastatin in only 18 asymp-
tomatic hypercholesterolaemic patients, with carotid
CMR alone demonstrating a reduction of 15% in carotid
vessel wall area after 1 year of statin use [14,29]. We per-
formed a placebo-controlled, double-blind 3D carotid
CMR study to evaluate the effect of rosiglitazone on
atherosclerosis burden in patients with type 2 diabetes
mellitus.
Methods
This was a randomized, placebo-controlled, double-blind
study in patients with type 2 diabetes and coexisting vas-
cular disease or hypertension. After completing a 4–8
week single-blind placebo run-in period, eligible subjects
entered a 52 week double-blind treatment period during
which they received either rosiglitazone (4 mg once daily
for the first 12 weeks and then 4 mg twice daily for the
remainder of the study) or placebo. Randomization was
performed in a 1:1 manner to the rosiglitazone or placebo
treatment group using the Registration and Medication
Ordering System (RAMOS), and stratified by statin or
fibrate use without distinction between the two.
Eligible patients were those with type 2 diabetes, aged
between 30–75 years, HbA1c <10% at screening who had
been treated with diet and exercise alone or metformin or
a sulphonylurea and had been stable prior statin or fibrate
dosage (for at least 3 months), and at least one atherom-
atous plaque causing 10–95% narrowing by ultrasound of
the internal carotid artery. Exclusion criteria included
more than two concomitant oral anti-hyperglycemic
agents (i.e. oral combination) within 3 months of the
screening visit or requirement for insulin. In total, 57 sub-
jects were entered into the placebo run-in phase of the
study and were subsequently randomized to receive dou-
ble-blind medication in addition to background anti-dia-
betic therapy: 28 to rosiglitazone and 29 to placebo. The
study protocol defined targets for glucose control during
the study to achieve equivalent glycemic control between
the groups. Following randomization, 3 patients did not
enter the treatment phase in the rosiglitazone arm. One
subject was not suitable for CMR and was not entered into
the safety population. Two subjects were subsequently not
entered into the intention to treat population (ITT)
because of withdrawal of consent (1), and loss to follow-
up (1). Twenty-one patients in the rosiglitazone group
and 26 patients in the placebo group went on to complete
both the baseline and 52 week CMR scans (figure 1).
The study was conducted in accordance with good clinical
practice guidelines, all applicable regulatory require-
ments, the guiding principles of the Declaration of Hel-Journal of Cardiovascular Magnetic Resonance 2009, 11:24 http://www.jcmr-online.com/content/11/1/24
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sinki, and was approved by the ethics committee. Subjects
gave written informed consent. The primary endpoint of
the study was total carotid atherosclerosis volume, as
measured by carotid CMR arterial wall volume, following
52 weeks oral treatment with rosiglitazone compared to
placebo.
Carotid CMR at baseline and week 52 was performed on
a 1.5 Tesla scanner (Sonata, Siemens, Erlangen, Germany)
with purpose-built bilateral four channel phased-array
surface carotid coils (Machnet BV, The Netherlands), and
a specially designed head and neck cushion with air-
extraction for immobilization. Subjects were scanned in
the supine position with the carotid coils in the magnet
isocentre. T1 weighted 3D black-blood acquisitions were
obtained predominantly unilaterally on the side of
known carotid narrowing in all patients, and if possible
bilaterally. Bilateral acquisitions were attempted if there
was confirmed bilateral carotid artery disease, adequate
image quality, and subjects could tolerate the additional
imaging period. Typical sequence parameters were: matrix
size = 256, 0.47 mm × 0.47 mm pixels; 28 slices of 2 mm
thickness; typical field-of-view = 120 mm × 24 mm; time
to echo = 11 ms; repetition time according to a single mul-
tiple of the subject's R-R interval; echo train length = 11;
fat suppression; and 650 ms inversion time following
double inversion preparation pulse during free-breathing.
Acquisitions took between 2 – 4 minutes. The region cho-
sen for all measurements were centered either side of the
carotid bifurcation, extending 28 mm in both directions
to give 56 mm of total vessel coverage. All scans for anal-
ysis were made perpendicular to the long-axis of the
carotid artery.
The total carotid artery wall volume was calculated by sub-
tracting total carotid luminal volume from the total vessel
wall volume using semi-automated contouring software
named Atheroma-Tools, (a plug-in of CMRtools, Cardio-
vascular Imaging Solutions, London, UK) [30]. This soft-
ware models the 3D vessel with only minimal assistance
from the operator (figure 2), and has been shown to facil-
itate greater vessel coverage than manual delineation.
Contouring was performed by a single observer (AV).
Statistical analysis was performed by GlaxoSmithKline
(GSK) from raw blinded information. CMR endpoints
were collected separately for the left and right carotid
arteries and summed for analysis where indicated. Data
analysis was by ITT on the patients who were randomized,
received at least one dose of medication, and had at least
one post-baseline value for at least one efficacy parameter
(rosiglitazone 25, placebo 29). The safety population
comprised 27 patients on rosiglitazone and 29 on pla-
cebo. Summary data are presented as mean ± SD with sep-
arate calculations for each stratum within each treatment
group for the total carotid wall volume at 52 weeks. The
Baseline high-resolution left carotid CMR performed on a 63  year old male study participant at the level of the a) internal  carotid artery, b) carotid artery bifurcation, and c) common  carotid artery, with the corresponding levels (arrowed) on  the 3D model shown in d) Figure 2
Baseline high-resolution left carotid CMR performed 
on a 63 year old male study participant at the level of 
the a) internal carotid artery, b) carotid artery bifur-
cation, and c) common carotid artery, with the cor-
responding levels (arrowed) on the 3D model shown 
in d). CC – common carotid artery, IC – internal carotid 
artery, EC – external carotid artery.
Patient recruitment, randomization and completion Figure 1
Patient recruitment, randomization and completion. 
ITT – Intention to treat.Journal of Cardiovascular Magnetic Resonance 2009, 11:24 http://www.jcmr-online.com/content/11/1/24
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adjusted mean treatment difference between rosiglitazone
and placebo is presented with a 95% two-sided CI and
associated P value, with the change in total carotid wall
volume from baseline to end of treatment being analyzed
using parametric analysis of covariance (ANCOVA). Sam-
ple size calculations had shown that with 30 subjects per
group, the study had 90% power to detect a relative effect
size of 0.85.
Results
Study population and safety profile
The demographic profile for all subjects who had received
at least one dose of study medication (safety population)
is summarized in table 1, and the baseline lipid lowering
and anti-hypertensive medication in table 2. At baseline,
the proportion of subjects who had received previous
lipid-lowering or anti-hypertensive medication was
slightly lower in the rosiglitazone arm and this trend was
maintained at 52 weeks. Statin use at baseline was 67% (n
= 18) in the rosiglitazone group and 83% (n = 24) in the
placebo group (p = 0.221). By study termination, the cor-
responding values were 70% (n = 19) for rosiglitazone
and 93% (n = 27) for placebo (p = 0.038).
A serious adverse event was defined as any event which
was fatal, life threatening, disabling or incapacitating,
resulted in hospitalization or prolonged a hospital stay, or
was associated with a congenital abnormality or birth
Table 1: Demographic characteristics of safety population
Rosiglitazone Placebo Total P value
N (%) (N = 27) (N = 29) (N = 56)
Gender
Male 21 (78%) 23 (79%) 44 (79%) P = 0.85
Female 6 (22%) 6 (21%) 12 (21%) P = 0.85
Age (years)
Mean ± SD 62.2 ± 8.2 65.6 ± 6.1 63.9 ± 7.4 P = 0.072
Median 65.0 66.0 65.0
Range 38 – 74 55 – 75 38 – 75
Race
White 17 (63%) 18 (62%) 35 (63%) P = 0.84
Black 3 (11%) 4 (14%) 7 (13%) P = 1.00
Oriental 1 (4%) 0 1 (2%) P = 0.48
Other 6 (22%)
Asian-4, Bangladeshi-1, Brazilian-1
7 (24%)
Asian-4, Bangladeshi-1, Indian-1, Yemeni-1
13 (23%) P = 0.88
Statin/fibrate use
Yes 21 (78%) 24 (83%) 45 (80%) P = 0.90
No 6 (22%) 5 (17%) 11 (20%) P = 0.89
Smoking history
Never 6 (22%) 12 (41%) 18 (32%) P = 0.21
Former 16 (59%) 13 (45%) 29 (52%) P = 0.42
Current 5 (19%) 4 (14%) 9 (16%) P = 0.73
Number of years smoked1
Mean ± SD 33.5 ± 12.7 34.3 ± 14.8 33.9 ± 13.5 P = 0.83
Median 32.0 39.0 34.0
Range 7 – 63 7 – 56 7 – 63
Number of cigarettes per day1
Mean ± SD 22.9 ± 21.5 21.7 ± 13.8 22.3 ± 18.2 P = 0.80
Median 20.0 20.0 20.0
Range 3 – 100 3 – 60 3 – 100
Weight (kg)
Mean ± SD 78.1 ± 13.8 81.8 ± 14.1 80.0 ± 13.9 P = 0.59
Median 77.4 80.5 79.0
Range 60.5 – 117.4 56.0 – 116.2 56.0 – 117.4
Height (cm)
Mean ± SD 167.3 ± 8.8 169.0 ± 6.2 168.2 ± 7.6 P = 0.40
Median 170.0 169.0 169.0
Range 151 – 187 157 – 179 151 – 187
BMI (kg/m2)
Mean ± SD 27.9 ± 4.1 28.6 ± 4.3 28.3 ± 4.2 P = 0.77
Median 27.9 28.5 28.0
Range 22.4 – 39.2 20.6 – 37.1 20.6 – 39.2
1. Data only for current and former smokers (rosiglitazone group-21; placebo group-17).Journal of Cardiovascular Magnetic Resonance 2009, 11:24 http://www.jcmr-online.com/content/11/1/24
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defect. Additionally, any event which the investigator
regarded as serious or which would suggest any significant
hazard, contraindication, side effect or precaution that
may have been associated with the use of the drug was
documented as a serious event. Two subjects in the rosigl-
itazone arm (7%; worsening of myocardial ischaemia and
angina) and one subject in the placebo group (3%;
angina) had cardiac ischemic events. There were two
reports of congestive cardiac failure, both in the rosiglita-
zone group. Two subjects in each group had edema. There
were no deaths during the study. Compliance with study
tablets, measured as taking 80 – 120% of medication, was
85% for rosiglitazone and 97% for placebo (p = 0.185).
Glycemia and lipid profile
At the end of treatment, there was a significant change
from baseline in HbA1c in the rosiglitazone group com-
pared with the placebo group (-0.88%, P < 0.001). The
changes from baseline in lipid parameters by end of treat-
ment are shown in table 3.
Changes in total carotid arterial wall volume
The change in carotid arterial wall volume from baseline
to week 52 is summarized in table 4. At baseline, the
carotid wall volume in the placebo group was 1146 ± 550
mm3 and in the rosiglitazone group was 1354 ± 532 mm3.
After 52 weeks, the respective carotid wall volumes were
1134 ± 523 mm3 and 1348 ± 531 mm3, which was a mean
decrease from baseline of 12.1 mm3 and 5.7 mm3. These
changes were small (<1%) and not statistically significant
between groups (P = 0.57).
Discussion
This study demonstrated that rosiglitazone had no signif-
icant effect on carotid atheroma compared with placebo
over 52 weeks. This is in contrast to Stocker's study [13],
where they showed a significant change in the maximal
and mean carotid IMT between the rosiglitazone and met-
formin groups. Pioglitazone has also been shown to
reduce carotid IMT, independently of glycemic control in
type 2 diabetes, even over 12 weeks of treatment [31].
Beneficial effects for PPARγ agonists were also shown in
rabbits using CMR of the aorta [32]. Atherosclerosis was
induced by double-balloon injury and a 9 month high-
cholesterol diet and the rabbits were then randomized
into 5 groups: continued high-cholesterol diet, normal-
chow diet, normal-chow diet plus simvastatin, normal-
chow plus L-805645 (a selective PPARγ agonist), and nor-
mal-chow plus simvastatin plus L-805645. Plasma choles-
terol levels remained elevated in the high-cholesterol diet
group but fell to similar levels in the other groups, regard-
less of treatment. Normalization of lipid levels in the nor-
mal-chow group halted the atheroma progression seen in
the high-cholesterol group, but did not induce regression.
Regression was only achieved in the groups receiving sim-
vastatin, with the greatest effect in the group on both drug
therapies. However, use of the PPARγ agonist alone had
no significant effect on atheroma reduction, but did not
cause progression. These findings suggested an additive
anti-atherogenic effect of a statin and PPARγ agonist in the
presence of a neutral lipid profile.
Recent meta-analyses suggesting an increased risk of myo-
cardial infarction using rosiglitazone have had a negative
impact on the clinical use of thiazolidinediones in type 2
diabetes, especially rosiglitazone [33,34], despite ongoing
debate and the inconclusive interim report from the Ros-
iglitazone Evaluated for Cardiac Outcomes and Regula-
tion of Glycemia in Diabetes (RECORD) study [35]. Our
data demonstrate that rosiglitazone had no significant
effect on carotid atheroma compared with placebo over
52 weeks. These findings mirror data regarding pioglita-
Table 2: Baseline lipid-lowering and anti-hypertensive medications
Rosiglitazone Placebo P value
N (%) (N = 27) (N = 29)
Any such medication 26 (96%) 29 (100%)
Lipid-Lowering Medication 21 (78%) 24 (83%) P = 0.89
Statin 18 (67%) 24 (83%)
Fibrate 3 (11%) 2 (7%)
Other lipid-lowering agents 1 (4%) 1 (3%)
Anti-Hypertensive Medication 24 (89%) 29 (100%) P = 0.23
Diuretic 13 (48%) 10 (34%)
ACE inhibitor 12 (44%) 16 (55%)
Calcium channel antagonist 11 (41%) 19 (66%)
Beta-blocker 9 (33%) 14 (48%)
Alpha-blocker 4 (15%) 8 (28%)
Angiotensin 2 antagonist 2 (7%) 3 (10%)
NB Some subjects had been prescribed more than one lipid-lowering or anti-hypertensive medication.Journal of Cardiovascular Magnetic Resonance 2009, 11:24 http://www.jcmr-online.com/content/11/1/24
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zone as assessed by coronary intravascular ultrasound
(IVUS) [36]. Therefore, there is comparable data for piogl-
itazone and rosiglitazone, but contradictory histopatho-
logical data for L-805645.
Individual lipid pharmacokinetics may explain these dif-
ferential results between drugs [37-39]. The ADOPT study
showed that rosiglitazone raised LDLc compared to met-
formin, necessitating a greater use of lipid-lowering ther-
apy [40]. In our study cohort, statin use was greater in the
placebo group, which may have confounded our results,
given the known anti-atherosclerotic effects of statins.
Measured lipid parameters showed that values for HDLc
increased and triglycerides decreased in both treatment
groups, but there were small decreases at week 52 in total
cholesterol and LDLc in the placebo group but little
change in the rosiglitazone group.
Table 3: Lipid profile changes in the ITT population.
Lipid parameter Rosiglitazone Placebo
(mmol/L) (N = 25) (N = 29)
Total Cholesterol
Baseline geometric mean 4.14 4.36
(-SE, +SE) 3.97, 4.33 4.15, 4.58
End of treatment geometric mean 4.13 4.17
(-SE, +SE) 3.97, 4.29 3.97, 4.37
% Change geometric mean -0.5 -4.5
(-SE, +SE) -3.24, 2.40 -8.00, -0.85
P value 0.42
HDLc
Baseline geometric mean 1.10 1.14
(-SE, +SE) 1.04, 1.15 1.06, 1.22
End of treatment geometric mean 1.16 1.22
(-SE, +SE) 1.09, 1.22 1.15, 1.29
% Change geometric mean 5.4 7.2
(-SE, +SE) 1.41, 9.55 3.35, 11.1
P value 0.97
LDLc
Baseline geometric mean 2.22 2.31
(-SE, +SE) 2.07, 2.37 2.16, 2.47
End of treatment geometric mean 2.23 2.13
(-SE, +SE) 2.10, 2.36 1.98, 2.28
% Change geometric mean 0.4 -7.9
(-SE, +SE) -4.07, 5.10 -12.7, -2.82
P value 0.24
Triglycerides
Baseline geometric mean 1.61 1.67
(-SE, +SE) 1.50, 1.72 1.52, 1.84
End of treatment geometric mean 1.35 1.48
(-SE, +SE) 1.24, 1.47 1.36, 1.61
% Change geometric mean -16.0 -11.6
(-SE, +SE) -22.4, -9.13 -18.1, -4.65
P value 0.70
Free fatty acids
Baseline geometric mean 0.58 0.56
(-SE, +SE) 0.55, 0.62 0.53, 0.59
End of treatment geometric mean 0.46 0.60
(-SE, +SE) 0.42, 0.50 0.57, 0.64
% Change geometric mean -20.7 7.8
(-SE, +SE) -28.00, -12.6 2.86, 12.9
P value 0.0050
There were no significant between groups differences
% Change based on log-transformed data: 100* [exp (mean change on log scale) – 1].Journal of Cardiovascular Magnetic Resonance 2009, 11:24 http://www.jcmr-online.com/content/11/1/24
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Two coronary IVUS studies are of interest with regard to
our study findings [41,42]. The REVERSAL trial quantified
intracoronary atheroma volume following 18 months of
treatment with 40 mg pravastatin versus 80 mg of atorvas-
tatin. The moderate lipid-lowering regimen using pravas-
tatin led to an increase in coronary atherosclerosis, while
the intensive regime with atorvastatin showed absence of
plaque progression over that same time period. In the
ASTEROID trial, 24 months of high intensity rosuvastatin
treatment (40 mg) for 24 months was needed to demon-
strate coronary plaque volume reduction. This IVUS data
highlights that the absence of regression of carotid
atheroma over 52 weeks using rosiglitazone in the context
of established lipid-lowering management is not unex-
pected. Also, longer study duration with more subjects
would have been optimal, with repeat carotid CMR at 24
months. Our initial power calculations required 30 sub-
jects in each arm to identify a relatively large treatment
effect. However as the carotid atheroma volume changes
were smaller than predicted our study was relatively
underpowered and a 24 month carotid CMR may clarify
the trend noted in carotid plaque volume between pla-
cebo and drug treatment. However, our findings are in
line with recent data from the APPROACH study. This
randomized 672 type 2 diabetic patients to either the sul-
fonylurea glipizide or rosiglitazone for 18 months and
evaluated coronary atheroma using IVUS. These investiga-
tors found that rosiglitazone did not lead to atheroma
progression or regression compared to glipizide.
Increased plaque volume is only one component of the
propensity of plaque to rupture. In vivo, serial, noninva-
sive carotid CMR quantification of atheroma over one
year reflects changes in overall plaque burden and indi-
vidual plaque constituents such as smooth muscle cells,
and collagen [35,43]. More detailed plaque interrogation
is possible with both IVUS and CMR, and such data would
provide important additional insights into the possible
increased risk [37].
Conclusion
In conclusion, 52 weeks of treatment with rosiglitazone
had no effect on progression of carotid atheroma volume
in patients with type 2 diabetes mellitus compared to pla-
cebo. Increased cardiovascular risk attributed to rosiglita-
zone cannot simply be related to increased atherosclerotic
burden, and other potential mechanisms need to be con-
sidered. The adverse effects of the thiazolidinediones need
to be balanced against their benefits and there should be
caution with the use of surrogate markers for hard clinical
end-points [44-46].
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